Financials • TScan Therapeutics

TCRX

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2019	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2020	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2021	10	-45	-12	L	L	161	L	-161	-	-51	-10	190	-61	0	0	-	-
12/2022	14	-61	-12	L	L	99	L	-91	-	-71	-4	29	-75	0	0	-	-
12/2023	21	-88	-12	L	L	151	L	-165	-	-67	-3	135	-70	0	0	-	-
12/2024	3	-131	-123	L	L	241	L	-258	-	-120	-4	209	-124	0	0	-	-
12/2025	10	-133	-123	L	L	123	L	-120	-	-147	-4	-0	-151	0	0	-	-

To see all financials—including updated, you must be Premium.